Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iradimed (IRMD) Cost of Revenue (2016 - 2025)

Iradimed (IRMD) has disclosed Cost of Revenue for 13 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 24.04% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.4 million, a 42.02% increase, with the full-year FY2024 number at $15.6 million, up 28.61% from a year prior.
  • Cost of Revenue was $4.7 million for Q3 2025 at Iradimed, up from $4.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $4.7 million in Q3 2025 to a low of $777299.0 in Q4 2023.
  • A 5-year average of $3.4 million and a median of $3.7 million in 2022 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: tumbled 78.79% in 2023, then surged 481.18% in 2024.
  • Iradimed's Cost of Revenue stood at $3.1 million in 2021, then grew by 17.43% to $3.7 million in 2022, then crashed by 78.79% to $777299.0 in 2023, then soared by 481.18% to $4.5 million in 2024, then increased by 4.21% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Cost of Revenue are $4.7 million (Q3 2025), $4.0 million (Q2 2025), and $4.2 million (Q1 2025).